Biopharmaceuticals

Barcelona – October 06, 2026 -- Veeva Systems (NYSE: VEEV) said its Data Quality System (DQS) has aggregated and cleaned data for more than 1 million subjects across over 1,000 clinical studies, automating over 500,000 queries and eliminating thousands of hours of manual data reconciliation for sites and sponsors.

Veeva DQS automates over 500,000 queries to speed analysis-ready data delivery

The platform classifies and visualizes critical trial data while orchestrating risk-based actions across the clinical ecosystem, removing manual reconciliation steps that have historically slowed data lock and submission timelines.

Novo cites rising trial data volume as key driver for automated data management

Ibrahim Kamstrup-Akkaoui, vice president at Novo, said managing data from a growing number of clinical trials is a priority, and that Veeva DQS helps the company manage, format, clean, and prepare data for submission more efficiently.

San Diego – October 06, 2026 -- Viking Therapeutics (NASDAQ: VKTX) has initiated Part 2 of a maintenance dosing study for VK2735, its dual GLP-1/GIP receptor agonist, testing oral tablet regimens alongside subcutaneous options to sustain weight loss after initial treatment.

Trial enrolls 195 obese adults to test five maintenance pathways

The randomized, double-blind, placebo-controlled study will enroll approximately 195 adults with obesity (BMI ≥30 kg/m2). All participants first receive 21 weeks of weekly subcutaneous VK2735 or placebo before transitioning to one of five maintenance arms: daily oral doses, weekly oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo. The study runs through Week 33, tracking safety, tolerability, pharmacokinetics, and body weight change from baseline and from Week 21.

Dover, Delaware – October 06, 2026 -- The Digital CMC Consortium has launched as a new industry collaboration aimed at the end-to-end digitalization of Chemistry, Manufacturing, and Controls (CMC) processes in drug development. Founding participants include Novartis, Thermo Fisher Scientific, Takeda, Rockwell Automation, Flagship's Pioneering Medicines, Stellix, ZS Associates, and QbDVision.

Consortium targets legacy PDF-based workflows that bottleneck drug development

The CMC phase of pharmaceutical development remains tethered to manual, document-based processes that treat PDF tables as the source of truth, despite rapid advances in drug discovery and clinical trial digitization elsewhere in the industry. The Consortium aims to convert static CMC knowledge into reusable, interoperable digital assets to improve speed, quality, and regulatory confidence.

Lexington – October 06, 2026 -- Piramal Pharma Solutions (PPS) has opened a new microbiology laboratory at its Lexington site that more than triples existing testing space and is expected to cut testing times by up to 50%.

New Grade A isolator doubles sterility testing capacity at the site

The facility's centerpiece is a fully integrated, Grade A sterility testing isolator housed within a dedicated suite with a Grade C background environment, a major upgrade from the previously non-classified testing area. The isolator supports both open and closed filtration methods and allows multiple samples to be processed simultaneously, doubling the site's sterility testing capacity.

Leiden – – October 06, 2026 -- Qurin has launched the Qatra Genomic DNA Extraction Lab Kit (RUO), a Research Use Only product capable of processing urine volumes up to 400 mL, a full void, compared with the 40-50 mL standard in conventional laboratory workflows.

Qatra kit delivers 7.6-fold increase in DNA yield in internal studies

In internal studies, average DNA yields rose 7.6-fold as sample volume increased from 50 mL to 400 mL. Qurin states this volume expansion could allow researchers to recover substantially more biomarker material from a single sample, particularly relevant when target DNA is present at low concentrations.

Oxford, England – October 06, 2026 -- Perspectum, an Oxford-based precision health company, has appointed Warren Cresswell as Chief Executive Officer, bringing more than 25 years of diagnostics and medical device leadership to the firm's push into liver and cardiometabolic disease imaging. The placement was executed by Slone Partners, a nationwide executive search firm serving life sciences and healthcare organizations.

Cresswell previously led Nestlé-owned Prometheus Laboratories through a growth phase

Cresswell served as President and CEO of Prometheus Laboratories, a Nestlé Health Science company, where he directed the diagnostics business through a period of significant expansion. He has built commercial and CLIA-certified laboratory infrastructure supporting FDA-cleared diagnostics in the United States and most recently served as CEO of a precision oncology company.

Portland – October 06, 2026 -- Headlands Research - Summit Portland is marking 50 years of operation in 2026, having contributed clinical research to every FDA-approved class of Alzheimer's disease medication brought to market since 1993. The site, founded in 1976, has conducted more than 500 clinical trials in partnership with pharmaceutical companies and contract research organizations (CROs).

SEATTLE – October 05, 2026 -- Mozart Therapeutics presented three new data sets on its lead candidate MTX-101 at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), held September 28–October 2, 2026, in Milan, Italy, advancing the bispecific antibody toward a planned Phase 2a trial in Stage 3 type 1 diabetes with enrollment targeted for the first half of 2027.

Phase 1a/b data show MTX-101 is well tolerated and may affect C-peptide levels

The first presentation detailed safety, pharmacokinetic and pharmacodynamic results from a Phase 1a/b study in healthy adults and type 1 diabetes patients. Clinical data collected to date indicate MTX-101 has been relatively safe and well tolerated, with early signals suggesting a positive effect on C-peptide levels in patients with Stage 3 disease.

San Rafael, Calif. – October 05, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) appointed Cara Bauer, Ph.D., as Executive Vice President, Chief People Officer, effective Oct. 5, 2026, succeeding Amy Wireman, who is retiring after nearly 14 years at the company.

Bauer arrives with 25 years of HR leadership across biotech and technology

Bauer joins BioMarin from Kyverna Therapeutics, Inc., where she served as Chief Human Resources Officer starting October 2024. She previously held the role of global head of human resources at Kite, a Gilead company, and led HR for the entertainment division at Riot Games. Earlier in her career she held HR leadership positions at Netflix, Amgen and Novo Nordisk.

North Chicago / Copenhagen – October 05, 2026 -- AbbVie and Genmab A/S reported that epcoritamab combined with standard R-CHOP chemotherapy reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients, based on topline Phase 3 data.

Trial hits statistical significance with hazard ratio of 0.49

The Phase 3 EPCORE DLBCL-2 study showed a hazard ratio of 0.49 (95% CI 0.36-0.67; p-value less than 0.0001) for progression-free survival in patients with an International Prognostic Index (IPI) score of 2 to 5. For the trial's primary endpoint population, patients with IPI scores of 3 to 5, the hazard ratio was also 0.49 (95% CI 0.35-0.69; p-value less than 0.0001).